Generic Exclusivity Debate Continues At FDA: What Counts As A Forfeit?
Executive Summary
FDA is continuing its case-by-case review of the 180-day exclusivity status for ANDAs as they approach marketing - most recently for generics of Bayer's Precose (acarbose), King's Altace (ramipril) and Roche's Kytril (granisetron)
You may also be interested in...
Altace ANDAs On Hold Till June; Colbalt Gets Exclusivity, Not “Parking” Ticket
Lupin Pharmaceuticals and five other pharma companies will have to wait at least until June to market their versions of ramipril capsules (King's Altace), as FDA ruled that Cobalt Pharmaceuticals is entitled to the 180-day generic drug exclusivity it was granted in 2005
Altace ANDAs On Hold Till June; Colbalt Gets Exclusivity, Not “Parking” Ticket
Lupin Pharmaceuticals and five other pharma companies will have to wait at least until June to market their versions of ramipril capsules (King's Altace), as FDA ruled that Cobalt Pharmaceuticals is entitled to the 180-day generic drug exclusivity it was granted in 2005
Generic Exclusivity Triggers May Force Re-evaluation Of Brand/Generic Deals
FDA's consideration of how brand/generic settlements would impact generic exclusivity may be causing firms to reconsider the arrangements